GLYNASE PRESTAB Rx
Generic Name and Formulations:
Glyburide, micronized 1.5mg, 3mg, 6mg; scored tabs.
Indications for GLYNASE PRESTAB:
Adjunct to diet and exercise in type 2 diabetes.
Initially 1.5–3mg daily with breakfast. Debilitated: initially 0.75mg daily with breakfast. Increase by 1.5mg at weekly intervals if needed per blood glucose. Maintenance: 0.75–12mg daily in single or divided doses (consider divided doses above 6mg daily); max 12mg daily.
Initially 0.75mg daily with breakfast.
Diabetic ketoacidosis, with or without coma. Type 1 diabetes. Concomitant bosentan.
Increased risk of cardiovascular mortality. Impaired renal or hepatic function. Stress. Secondary failure may occur with extended therapy. Discontinue if jaundice or persistent rash occurs. G6PD deficiency; consider non-sulfonylurea alternative. Monitor urine, blood glucose, and glycosylated hemoglobin. Retitrate if transfer from other glyburide containing or hypoglycemic agents (see full labeling). Elderly, debilitated, malnourished, adrenal or pituitary insufficiency, severe/prolonged exercise: increased risk of hypoglycemia. Pregnancy (Cat.B): consider using insulin instead; if glyburide needed, discontinue ≥2 weeks before delivery date. Nursing mothers: not recommended.
Elevated liver enzymes with concomitant bosentan (see Contraindications). Increased risk of hypoglycemia with concomitant alcohol or other hypoglycemics. Potentiated by NSAIDs, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, β-blockers. Antagonized by diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, niacin, sympathomimetics, calcium channel blockers and isoniazid. May be potentiated by ciprofloxacin, oral miconazole. Administer glyburide >4hrs prior to colesevelam. Disulfiram-like reaction with alcohol (rare). Monitor for 2 weeks if transferring from chlorpropamide.
Sulfonylurea (2nd generation).
Hypoglycemia, cholestatic jaundice (rare), nausea, epigastric fullness, heartburn, allergic skin reactions, photosensitivity, blood dyscrasias, hepatic porphyria, hyponatremia.
PresTab 1.5mg—100; 3mg—100, 500, 1000; 6mg—100, 500
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Self-Predictions for Well-Being Influence Satisfaction After Mastectomy, Breast Reconstruction
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Gabapentin Improves Postoperative Opioid Cessation, But Not Pain Resolution
- Early Integration of Palliative Care Improves Quality of Life in Advanced Cancer
- Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Cachexia Not Improved With Celecoxib Plus Megestrol vs Megestrol Alone
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Efficacy and Safety of COX-2 Inhibitors for Advanced Non-small-cell Lung Cancer With Chemotherapy: A Meta-analysis
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|